TP53 and small cell lung carcinoma: The inhibition of CDK7 using the selective inhibitor YKL-5-124 has been shown to have a synthetic lethal effect when combined with a TP53 activator; this can disrupt cell cycle progression, induce DNA replication stress, and trigger genome instability in SCLC (83).